Clinigen gains US FDA approval for Foscavir in HIV/AIDS-related ... MarketWatch (press release) Clinigen and BL&H are collaborating to secure Korean marketing authorizations for Foscavir, both in its primary indications and as a treatment for CMV in hematopoietic stem cell transplant (HSCT) patients (bone marrow transplants). |
